Osteoporosis Drugs Global Market Report 2025

Description

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12.33 billion in 2024 to $12.8 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to aging population, increased awareness and diagnosis, lifestyle factors, government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to continued aging population trends, advancements in treatment options, increased focus on men's bone health, patient education and empowerment, global health policies and insurance coverage. Major trends in the forecast period include personalized medicine approaches, exploration of combination therapies, focus on fracture prevention strategies, R&D investment in novel drug targets, collaborations for drug development.

An increase in the prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis is a bone condition characterized by a decrease in bone mineral density and mass or changes in bone quality and structure. Individuals with low calcium intake are at a higher risk of developing osteoporosis. These osteoporosis medications work to enhance bone mineral density and reduce the likelihood of fractures. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that osteoporosis was responsible for 2,659 deaths in 2022, which equates to 10.2 deaths per 100,000 people, accounting for 1.4% of all deaths. Thus, the rising prevalence of osteoporosis is propelling the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company that offers various pharmaceutical products, acquired EffRx Pharmaceuticals for an undisclosed amount. With this acquisition, Abiogen Pharma intends to bolster its international presence, enhance its product offerings in bone health, leverage synergies for more effective drug development, and concentrate on rare diseases. EffRx Pharmaceuticals, a Switzerland-based company, specializes in creating innovative treatments for osteoporosis, aiming to improve bone density and minimize fracture risk. Their therapies focus on specific biological pathways to promote bone health in patients suffering from this condition.

Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
2) By Administration: Oral; Injectable
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
4) By Application: Primary Osteoporosis; Secondary Osteoporosis
Subsegments:
1) By Bisphosphonates: Alendronate; Risedronate; Ibandronate; Zoledronic Acid
2) By Selective Estrogen Receptor Modulators (SERMs): Raloxifene; Bazedoxifene
3) By RANK Ligand Inhibitors: Denosumab
Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co Inc.; Novartis AG; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r26829

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Osteoporosis Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Osteoporosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Osteoporosis Drugs Market Growth Rate Analysis
5.4. Global Osteoporosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Osteoporosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Osteoporosis Drugs Total Addressable Market (TAM)

6. Osteoporosis Drugs Market Segmentation

6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bisphosphonates
Selective Estrogen Receptor Modulators (SERMs)
RANK Ligand Inhibitors
6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacies
Hospital Pharmacies
Online Sales
6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Osteoporosis
Secondary Osteoporosis
6.5. Global Osteoporosis Drugs Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
6.6. Global Osteoporosis Drugs Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Raloxifene
Bazedoxifene
6.7. Global Osteoporosis Drugs Market, Sub-Segmentation Of RANK Ligand Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Denosumab

7. Osteoporosis Drugs Market Regional And Country Analysis

7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

8.1. Asia-Pacific Osteoporosis Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteoporosis Drugs Market

9.1. China Osteoporosis Drugs Market Overview
9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteoporosis Drugs Market

10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteoporosis Drugs Market

11.1. Japan Osteoporosis Drugs Market Overview
11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteoporosis Drugs Market

12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteoporosis Drugs Market

13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteoporosis Drugs Market

14.1. South Korea Osteoporosis Drugs Market Overview
14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteoporosis Drugs Market

15.1. Western Europe Osteoporosis Drugs Market Overview
15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteoporosis Drugs Market

16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteoporosis Drugs Market

17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteoporosis Drugs Market

18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteoporosis Drugs Market

19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteoporosis Drugs Market

20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

21.1. Eastern Europe Osteoporosis Drugs Market Overview
21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteoporosis Drugs Market

22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteoporosis Drugs Market

23.1. North America Osteoporosis Drugs Market Overview
23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteoporosis Drugs Market

24.1. USA Osteoporosis Drugs Market Overview
24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteoporosis Drugs Market

25.1. Canada Osteoporosis Drugs Market Overview
25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteoporosis Drugs Market

26.1. South America Osteoporosis Drugs Market Overview
26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteoporosis Drugs Market

27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteoporosis Drugs Market

28.1. Middle East Osteoporosis Drugs Market Overview
28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteoporosis Drugs Market

29.1. Africa Osteoporosis Drugs Market Overview
29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

30.1. Osteoporosis Drugs Market Competitive Landscape
30.2. Osteoporosis Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Osteoporosis Drugs Market Other Major And Innovative Companies

31.1. GlaxoSmithKline PLC
31.2. Eli Lilly and Company
31.3. Amgen Inc.
31.4. Novo Nordisk A/S
31.5. Asahi Kasei Pharma Corporation
31.6. Viatris Inc.
31.7. Teva Pharmaceutical Industries Ltd
31.8. Mylan N.V.
31.9. Daiichi Sankyo Company Limited
31.10. Sun Pharmaceutical Industries Ltd.
31.11. Ipsen
31.12. Kyowa Kirin Co Ltd.
31.13. Dr. Reddy's Laboratories Ltd.
31.14. Cipla Limited
31.15. Recordati S.p.A.

32. Global Osteoporosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

34. Recent Developments In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market High Potential Countries, Segments and Strategies

35.1 Osteoporosis Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Osteoporosis Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Osteoporosis Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer